The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Vanda Pharmaceuticals Inc shares valued at $32,130 were sold by Mitchell Stephen Ray on Jun 13 ’25. At $4.59 per share, Mitchell Stephen Ray sold 7,000 shares. The insider’s holdings dropped to 97,082 shares worth approximately $0.47 million following the completion of this transaction.
Also, Mitchell Stephen Ray purchased 7,000 shares, netting a total of over 32,159 in proceeds.
Before that, Polymeropoulos Mihael Hristos had added 10,000 shares to its account. In a trade valued at $43,995, the President and CEO bought Vanda Pharmaceuticals Inc shares for $4.40 each. Upon closing the transaction, the insider’s holdings increased to 10,000 shares, worth approximately $11.21 million.
As published in their initiating research note from H.C. Wainwright on October 31, 2024, Vanda Pharmaceuticals Inc [VNDA] has been a Buy and the price target has been revised to $18. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid July. As of February 25, 2022, Jefferies has decreased its “Buy” rating to a “Hold” for VNDA. Earlier on May 12, 2021, BofA Securities initiated its rating. Their recommendation was “a Buy” for VNDA stock.
Analyzing VNDA Stock Performance
On last trading session,, Vanda Pharmaceuticals Inc [NASDAQ: VNDA] rose 4.56% to $4.82. The stock’s lowest price that day was $4.54, but it reached a high of $4.835 in the same session. During the last five days, there has been a surge of approximately 6.40%. Over the course of the year, Vanda Pharmaceuticals Inc shares have dropped approximately -19.40%. Shares of the company reached a 52-week high of $5.19 on 03/06/25 and a 52-week low of $3.81 on 05/15/25.
Support And Resistance Levels for Vanda Pharmaceuticals Inc (VNDA)
According to the 24-hour chart, there is a support level at 4.63, which, if violated, would cause prices to drop to 4.44. In the upper region, resistance lies at 4.92. The next price resistance is at 5.03. RSI (Relative Strength Index) is 65.48 on the 14-day chart, showing neutral technical sentiment.
Is Vanda Pharmaceuticals Inc subject to short interest?
Stocks of Vanda Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.14 million shares to 4.73 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 4.87 million shares. A decline of -2.99% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.6 of the overall float, the days-to-cover ratio (short ratio) decline to 10.6.
Which companies own the most shares of Vanda Pharmaceuticals Inc (VNDA)?
In terms of Vanda Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 11 in the next 12 months, up nearly 138.61% from the previous closing price of $4.61. Analysts anticipate Vanda Pharmaceuticals Inc stock to reach 11 by 2025, with the lowest price target being 11. In spite of this, 2 analysts ranked Vanda Pharmaceuticals Inc stock as Buy at the end of 2025. On January 14, 2021, Citigroup assigned a price target of “a Neutral” to the stock and downgraded coverage with a $14.
